Alnylam Pharmaceuticals | ALNY - Umlaufvermögen

Aktienkurs
316.28
Täglich Wechseln
2.87 0.92%
Monatlich
-4.91%
Jährlich
24.96%
Q1 Prognose
303.95




Umlaufvermögen Veränderung Datum
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Arrowhead Research USD 1.17B 223.75M 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
Moderna USD 6.54B 54M 2025-12
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Novartis USD 28.2B 2.26B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.95B 8.99B 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Takeda JPY 3.12T 195.82B 2025-12
Tectonic Therapeutic USD 273.24M 17.61M 2025-09
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12
Xencor USD 599.82M 81.38M 2025-12